Another Chinese patent medicine centralized procurement alliance is coming!

After Hubei Alliance and Guangdong Alliance, the third regional alliance of Chinese patent medicine centralized procurement - Shandong Chinese patent medicine centralized procurement alliance has arrived! At present, only Beijing, Shanghai, Jiangsu, Zhejiang, Anhui and Guangxi have not formed a regional alliance of proprietary Chinese medicines; among the three regional alliances of Hubei, Guangdong and Shandong, many provinces and varieties overlap
.
The progress of the three regional alliances compared with the Shandong alliance According to the "Notice on Carrying out the Work of Traditional Chinese Medicine (Materials) in Public Medical Institutions in the Province" issued by the Shandong Provincial Medical Insurance Bureau, which was circulated on the Internet, in July 2020, the Shandong Provincial Medical Insurance Bureau initiated the establishment of a An inter-provincial Chinese medicine (material) procurement alliance composed of twelve provinces (autonomous regions and municipalities), and an Internet trading platform for the inter-provincial Chinese medicine (material) alliance has been established.
The alliance procurement function has now launched nearly 100 supply companies and more than 200 medical institutions, and the transaction volume has steadily increased
.
On December 12, 2021, under the guidance of the National Medical Insurance Bureau, the inter-provincial traditional Chinese medicine (materials) procurement alliance and the Sanming procurement alliance jointly held a meeting in Xiamen to merge and establish the national inter-provincial traditional Chinese medicine (materials) procurement alliance, led by Shandong to carry out traditional Chinese medicine (materials) procurement Procurement of decoction pieces, formula granules, and Chinese patent medicine alliance
.
How to regulate the many overlapping products of different alliances? As shown in Table 1, except for the newly added Ginkgo biloba extract, the reported volume of Chinese patent medicines in the Shandong Regional Alliance (rumored) is basically the sum of the varieties of the Hubei Regional Alliance and the Guangdong Regional Alliance.

.
Shandong is expected to be the third regional alliance to launch
.
There are many overlapping provinces and varieties among the three major regional alliances of Hubei, Guangdong and Shandong
.
So, for overlapping varieties, will medical institutions repeatedly report the volume on different platforms? According to the principle of purchasing with quantity, although it is very likely that medical institutions in Hubei Union, Guangdong Union and Shandong Union will obtain different prices for different quantities, but in actual purchases, medical institutions are likely to complete the purchase with the lowest price first, and the purchase price is the lowest.
Priority purchase for the most convenient delivery
.
How to formulate rules to regulate these overlapping products is worth studying
.
Focus on the complex Guangdong Alliance rules On December 24, 2021, the notice of "Guangdong Alliance Qingkailing and other Chinese patent medicines centralized procurement documents" was released
.
Compared with the draft released on September 14, 2021, the alliance of 7 provinces has changed to 6 provinces (Guangdong, Shanxi, Henan, Hainan, Ningxia, Qinghai), the number of products has changed from 134 to 132, and the composition and grouping of exclusive varieties The approach has also changed
.
How to combine different dosage forms of the same variety? From the perspective of grouping, the grouping of the Guangdong Alliance is more complicated than that of the Hubei Alliance
.
The Hubei Alliance uses the generic name and route of administration as the basis for grouping, while the Guangdong Alliance combines different dosage forms of the same variety of drugs into groups
.
Guangdong Alliance combines tablets, dispersible tablets, enteric-coated tablets, capsules and enteric-coated capsules into one group, soft capsules (capsules) and dripping pills into one group, granules, mixtures (oral liquids) and tinctures into one group, Pills (including water pills, honey pills, water honey pills, paste pills, concentrated pills and small pills, excluding dripping pills), concentrated water pills and concentrated water honey pills are combined into one group
.
The powders, rubber ointments, decoctions, oral emulsions, gels, sprays, suppositories and injections (including ordinary powder injection, lyophilized powder, solvent crystal, large-volume injection, and small-volume injection) are grouped separately
.
However, if an exclusive dosage form appears after the above-mentioned grouping, it shall be incorporated into a group of similar dosage forms that have a differential price relationship for the same route of administration
.
If the grouping still fails to be combined as an exclusive product (including the same variety of drugs with the same person in charge of the enterprise or different companies with direct holding and management relationships), the highest average daily cost or the highest effective declared price corresponding to the price declaration rules (Hereinafter referred to as P0) The values ​​after rounding to the nearest integer are divided into 3 groups: ①Value≤5 Yuan; ②5 Yuan<Value≤15 Yuan; ③Value>15 Yuan
.
The bid-winning specifications are first divided into exclusive and non-exclusive bid-winning specifications of the Guangdong Alliance are also the first to be divided into exclusive and non-exclusive.
The purchase order is the same as the Hubei Alliance, which is divided into A purchase order and B purchase order
.
Exclusive products only divide A purchase order
.
Theoretically, the total number of days of use for non-exclusive products according to the actual reported volume of the "28 Principles" accounts for the proportion of the total number of days of use for all enterprises in the entire alliance area, and the products of enterprises with a total of 80% of the proportion from high to low are listed in A procurement.
However, if the number of companies in the same group A purchase order is less than or equal to 2, they will be sorted according to the proportion from high to low, and the bidding of 3 companies will be filled
.
If this is the case, if the same group of B purchase orders is less than or equal to 2, they will be merged into A purchase order, and B purchase order will no longer be set
.
Details of the relationship between purchase volume and price Guangdong Province divides the purchase volume of the purchase order into two parts: P1 and P2
.
Only if the minimum average daily cost or minimum price of the non-exclusive product A purchase order drops by ≥15%, it is possible to obtain 70% of the pre-purchased volume in the first year and obtain incremental use
.
Regardless of whether it is non-exclusive or exclusive, the proportion of pre-purchased products in the first year of the product A purchase order is a corresponding increase of 5% for every 1% decrease.
The upper limit of non-exclusive products is 70%, and the upper limit of exclusive products is 100%
.
The winning bid of P2 is eliminated proportionally, not the last one
.
The elimination rate of non-exclusive product A purchase order product P2 is 50%, and up to 12 companies are included in the scope of winning the bid
.
The selection rate of exclusive product A purchase order product P2 is 70%, and the decrease of exclusive product A purchase order product or the lowest average daily cost or the lowest price (or without the lowest price of the company: the decrease of P2 and P0) is also more than 21%.
Eligible to be selected, only when P2 is selected can the exclusive product obtain 100% of the pre-purchased volume in the first year of the procurement period of the enterprise alliance region and gain incremental use
.
As a B purchase order to grab the market, the quotation of the enterprise is ≤ the lower value between the two, and it is sorted according to the "comparable price of the unit" from low to high, and the enterprises ranked in the top 50% (rounded up and reserved for single digits) are shortlisted; valid quotations With more than 24 companies, the top 12 companies were shortlisted
.
The shortlisted enterprises also require that their "unit comparable price" is not higher than the highest "unit comparable price" in the same group A purchase order P2, and the shortlisted enterprise is included in the scope of the proposed selection
.
The proportion of the pre-purchased volume in the first year of the procurement period of the company in the alliance area is 100% and the proportion of the company to be selected in the purchase order B will be used incrementally.

.
Who benefits? Who's bad? The Guangdong regional alliance rules are relatively favorable for products that have maintained market prices and have market foundations in the past
.
If the price of products in the blank market is not well maintained, they are basically not qualified to grab the market, and at the same time, they are also required to be lower than the highest purchase order P2 of the same group, and there is still a profit space under the "unit comparable price" to be selected.
volume market
.
This rule leaves no room for products that have previously been priceless
.
The Shandong Alliance is not optimistic about the price reduction Compared with the 41% price reduction of the Hubei regional alliance, the industry is even less optimistic about the price reduction of the Shandong Alliance
.
In December 2021, Shandong started the renewal of the national procurement contract.
Sinopharm Group Industry's dexmedetomidine injection 2ml: 0.
2mg won the bid at 4 yuan, a 97% drop compared with the lowest bid price of 133 yuan in the national procurement.
Compared with the announced renewal price of the Guangdong Regional Alliance of 7.
9 yuan, the price is halved
.
In addition, the contract renewal price of pemetrexed injection for centralized purchase fell below 100 yuan for the first time, with a price reduction of 88%
.
Shanghai Acrono's 250mg gefitinib tablet is 4.
1 yuan per tablet, a drop of 84%
.
Although the Shandong Alliance's rules have not been announced, from the perspective of the renewal policy, the Shandong Alliance's rules have fewer places and more participants, and the price of products with fierce competition can easily be directly pulled to the lowest
.
If the centralized procurement of Chinese patent medicines in the Shandong Regional Alliance continues to adopt this bidding strategy with a low number of successful bidders, it is expected that the price will be very unoptimistic
.